Akari Therapeutics Plc: Akari Therapeutics Announces Presentation of a Case Study from Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA as a Late-Breaker at The Transplantation & Cellular Therapy Tandem Meetings

NEW YORK and LONDON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases

Related Keywords

Florida ,United States ,United Kingdom ,Manchester ,Orlando ,London ,City Of ,American ,Dennis Riedl ,Mike Moyer ,Eliza Schleifstein ,Rob Wynn ,Research Professor ,Manchester University ,Division Of Bone Marrow Transplantation ,Nasdaq ,International Blood Marrow Transplant Research ,Akari Therapeutics Plc Nasdaq ,Foundation Trust In Manchester ,University Of Cincinnati Department Pediatrics ,Exchange Commission ,Clinical Response ,Thursday February ,Cellular Therapy Tandem Meetings ,Royal Manchester Children ,Professor Rob Wynn ,Professor Wynn ,Sonata Jodele ,Bone Marrow Transplantation ,Immune Deficiency ,Cincinnati Department ,American Society ,Cellular Therapy ,International Blood ,Marrow Transplant Research ,Orphan Drug ,Fast Track ,Rare Pediatric Disease ,Private Securities Litigation Reform Act ,Annual Report ,Hakari ,Herapeutics ,Nnounces ,Presentation ,Hase ,Study ,Rom ,Art ,Linical ,Trial ,Omacopan ,Pediatric ,Psct ,Gate ,Breaker ,Transplantation ,Ellular ,Therapy ,Tandem ,Meetings ,